CI 1.4 - 8.5) with celecoxib 400 mg twice daily and 2.8 (95% CI 1.1 - 7.2) with celecoxib 200 mg twice daily. Cumulative rates for this composite endpoint
METHODS Subjects received either celecoxib, 200 mg twice daily, for 5 days followed by celecoxib, 400 mg twice daily, for the next 5 days, or they received
In the APC (Adenoma Prevention with Celecoxib) trial, there was about a threefold increased risk of the composite endpoint of cardiovascular death, MI, or stroke for the celecoxib capsules 400 mg twice daily and celecoxib capsules 200 mg twice daily treatment arms compared to placebo.
Celecoxib, at doses up to 200 mg twice daily can be administered without regard to timing of meals. Higher doses (400 mg twice daily) should be administered
Celecoxib, at doses up to 200 mg twice daily can be administered without regard to timing of meals. Higher doses (400 mg twice daily) should be administered
Ankylosing Spondylitis (AS)/Osteoarthritis(OA)/Rheumatoid Arthritis (RA) Dosing for celecoxib: Celecoxib: AS: 200 mg once daily or 100 mg twice daily, up to 400
In the APC (Adenoma Prevention with Celecoxib) trial, there was about a threefold increased risk of the composite endpoint of cardiovascular death, MI, or stroke for celecoxib capsules 400 mg twice daily and celecoxib capsules 200 mg twice daily treatment arms compared to placebo.
Celecoxib, at doses up to 200 mg twice daily can be administered without regard to timing of meals. Higher doses (400 mg twice daily) should be administered
CI 1.4 - 8.5) with celecoxib. 400 mg twice daily and 2.8 (95% CI 1.1 - 7.2) with celecoxib 200 mg twice daily. Cumulative rates for this composite endpoint
Comments